close

Enter

Log in using OpenID

Tuberculosis Drugs Market

embed
Tuberculosis Drugs Market - Size, Share,
Growth, Outlook, and Opportunity Analysis,
2018-2026
Tuberculosis is a deadly infectious disease that affects the lungs. Among diseases, tuberculosis is the
second largest cause of death worldwide. Tuberculosis are broadly classified as latent tuberculosis
and active tuberculosis. Globally around 10% of latent infections develop into active tuberculosis.
Infections that do not show any symptoms are called latent tuberculosis. In 2015, the malady resulted
in 1.8 million deaths and 10.4 million new reported cases. In 2015, in the U.S., there were 9,557
tuberculosis cases reported. Based on the statistics of Center for Disease Control and Prevention, a
1.6% increase in the number of tuberculosis cases was observed in 2015 as compared to those
reported in 2014. Though there is an increase in the number of tuberculosis cases, the incidence rate
per 100,000 persons has been around 3.0 since 2013.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/191
Asia and Africa are the largest markets for tuberculosis drugs, as these regions have the highest
prevalence of TB. There are many initiatives taken to control the TB increasing cases. The United
Nations’ Millennium Development Goals have framed various strategies to reduce TB prevalence and
death rates by 2015, which can be achieved by WHO’s Stop TB Strategy. According World Health
Organization, in 2006, 61% out of 2.5 million new smear positive cases with DOTS, and are all the
new smear cases on the year, and the treatment was successful in 85% cases. The estimated global
incidence rate of tuberculosis shown decline rate by 0.6% in 2005 and 2006. In 2006, the incidence
rate of tuberculosis became stable in the Europe and is declining gradually in the other WHO
countries. World Health Organization has an approximation that the occurrence of tuberculosis and
death rates are declining faster than the incidence rate.
Tuberculosis is a chronic condition that is often undermined, though it can be fatal if left
unchecked. Thankfully, extensive awareness campaigns and initiatives by various governments
to curb the menace is bearing fruit. Tuberculosis treatment helped prevent 49 million fatalities
associated with the condition between 2000 and 2015. However, there are still some prominent
diagnostic and treatment slits that continue. In 2015, approximately 6.1 million newly diagnosed
tuberculosis cases were reported by national authorities of various countries and reported to
World Health Organization. This high increase in tuberculosis cases during 2013–2015, was
typically due to a 34% increase in tuberculosis cases notifications in India. Globally, there was
4.3 million new tuberculosis cases gap between incident and reported cases, out of which India,
Indonesia, and Nigeria comprises almost half of these newly diagnosed cases impacting high
revenue generation in tuberculosis drugs market.
Report includes chapters which deeply display the following deliverable about industry :
• Tuberculosis Drugs Market Research Objective and Assumption
• Tuberculosis Drugs Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Tuberculosis Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value
Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Tuberculosis Drugs Market, By Regions
• Tuberculosis Drugs Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Tuberculosis Drugs Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Tuberculosis Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Tuberculosis Drugs Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key companies covered as a part of this study include Pfizer Inc, Lupin Laboratories
Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd,
and Cipla Ltd.
Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-toanalyst/191
Detailed Segmentation:
• Global Tuberculosis Drugs Market, By Therapy Type:
• First Line Drugs Therapy
• Second Line Drugs Therapy
• Combination Drugs Therapy
• Global Healthcare Biometrics Market, By Geography:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Rushikesh
Rushikesh52   documents Email
Document
Category
Health and Medicine
Views
1
File Size
153 KB
Tags
tuberculosis
1/--pages
Report inappropriate content